Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,234
  • Shares Outstanding, K 2,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,580 K
  • 60-Month Beta 3.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.69
  • Number of Estimates 1
  • High Estimate -0.69
  • Low Estimate -0.69
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.71 +10.58%
on 11/26/19
11.78 -37.01%
on 11/21/19
-3.63 (-32.85%)
since 11/08/19
3-Month
6.71 +10.58%
on 11/26/19
13.34 -44.39%
on 10/21/19
-3.69 (-33.21%)
since 09/10/19
52-Week
1.61 +360.87%
on 01/22/19
73.52 -89.91%
on 03/07/19
+1.62 (+27.93%)
since 12/10/18

Most Recent Stories

More News
Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BPTH : 7.42 (-3.76%)
Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path: 3Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Friday reported a loss of $2.2 million in its third quarter.

BPTH : 7.42 (-3.76%)
Bio-Path Holdings Reports Third Quarter 2019 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 7.42 (-3.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade BPTH with:

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

2nd Resistance Point 8.08
1st Resistance Point 7.75
Last Price 7.42
1st Support Level 7.18
2nd Support Level 6.93

See More

52-Week High 73.52
Fibonacci 61.8% 46.05
Fibonacci 50% 37.56
Fibonacci 38.2% 29.08
Last Price 7.42
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar